PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Articles|September 2, 2020
- Pharmaceutical Technology-09-02-2020
- Volume 44
- Issue 9
Ultra-High Shear Mixer
Author(s)Pharmaceutical Technology Editors
MegaShear from Ross is a patented ultra-high shear rotor/stator mixer for high-throughput emulsification, dispersion, and homogenization.
MegaShear from Ross is a patented ultra-high shear rotor/stator mixer for high-throughput emulsification, dispersion, and homogenization. The device features 11,300 ft/min tip speed and can reach a level of shear typically only seen in high-pressure homogenizers.
The MegaShear Model HSM-706M-50 (pictured) comes equipped with a 50HP motor for creating high-quality dispersions, suspensions, and emulsions for the food, cosmetic, pharmaceutical and nutraceutical, chemical, coatings, electronics, and composites industries. The MegaShear is also less sensitive to clogging and changes in viscosity compared to other high-pressure homogenizers.
Articles in this issue
about 5 years ago
Moving Forward in Serializationabout 6 years ago
Preparing Pandemic Vaccine Capacityabout 6 years ago
Tracking API Quality During a Pandemicabout 6 years ago
Capsule Innovations: Speeding Up Drug Developmentabout 6 years ago
Manufacturing Drug–Device Combination Productsabout 6 years ago
Advancing Understanding of a Traditional Techniqueabout 6 years ago
Pharmacovigilance Under Scrutiny: Why Companies are Falling Shortabout 6 years ago
Pharmacopoeia Compliance: A Practical Guideabout 6 years ago
Streamlining Method Transfer Across Global SitesRelated to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.